• 1
    Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem 2006; 281:89979000.
  • 2
    CDC. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents–United States, 2005–2006 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55:4446.
  • 3
    Gubareva LV, Trujillo AA, Okomo-Adhiambo M et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010; 15:11511159.
  • 4
    Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10:123143.
  • 5
    Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012; 56:369377.
  • 6
    Sunagawa S, Higa F, Cash HL, Tateyama M, Uno T, Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respi Viruses 2013; 7:13.
  • 7
    Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:23952402.
  • 8
    Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000–2002 influenza seasons. Virus Res 2004; 103:195197.
  • 9
    CDC. Influenza activity–United States and worldwide, May 18-September 19, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:10461049.
  • 10
    Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:32843292.
  • 11
    Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–2008. Emerg Infect Dis 2009; 15:155162.
  • 12
    Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:pii8026.
  • 13
    Besselaar TG, Naidoo D, Buys A et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008; 14:18091810.
  • 14
    CDC. Update: influenza activity–United States, September 28, 2008-April 4, 2009, and composition of the 2009–2010 influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:369374.
  • 15
    Baranovich T, Saito R, Suzuki Y et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol 2010; 47:2328.
  • 16
    Graitcer SB, Gubareva L, Kamimoto L et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011; 17:255257.
  • 17
    Storms AD, Gubareva LV, Su S et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–2011. Emerg Infect Dis 2012; 18:308311.
  • 18
    Hurt AC, Hardie K, Wilson NJ et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011a; 365:25412542.
  • 19
    Hurt AC, Hardie K, Wilson NJ et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148157.
  • 20
    Hope-Simpson RE. The role of season in the epidemiology of influenza. J Hyg (Lond) 1981; 86:3547.
  • 21
    Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000; 280:291300.
  • 22
    Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 1979; 94:287296.
  • 23
    Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83:1036610373.
  • 24
    Okomo-Adhiambo M, Nguyen HT, Sleeman K et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 2010a; 85:381388.
  • 25
    Deyde VM, Gubareva LV. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev Mol Diagn 2009; 9:493509.
  • 26
    Deyde VM, Okomo-Adhiambo M, Sheu TG et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 2009; 81:1624.
  • 27
    Deyde VM, Sheu TG, Trujillo AA et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54:11021110.
  • 28
    Bolotin S, Robertson AV, Eshaghi A et al. Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. J Virol Methods 2009; 158:190194.
  • 29
    Hindiyeh M, Ram D, Mandelboim M et al. Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR. J Clin Microbiol 2010; 48:18841887.
  • 30
  • 31
    Okomo-Adhiambo M, Sleeman K, Ballenger K et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010b; 2:22692289.
  • 32
    Depoortere E, Mantero J, Lenglet A, Kreidl P, Coulombier D. Influenza A(H1N1)v in the southern hemisphere–lessons to learn for Europe? Euro Surveill 2009; 14:pii19246.
  • 33
    Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17(Suppl 1):S3S10.
  • 34
    Finkelman BS, Viboud C, Koelle K, Ferrari MJ, Bharti N, Grenfell BT. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PLoS ONE 2007; 2:e1296.
  • 35
    Kenah E, Chao DL, Matrajt L, Halloran ME, Longini IM Jr. The global transmission and control of influenza. PLoS ONE 2011; 6:e19515.
  • 36
  • 37
    CDC. Available at
  • 38
    Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 2010; 21:7184.
  • 39
    Tashiro M, McKimm-Breschkin JL, Saito T et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antivir Ther 2009; 14:751761.
  • 40
    Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62:3745.
  • 41
    McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:22642272.
  • 42
    Hurt AC, Lee RT, Leang SK et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011b; 16:pii19884.
  • 43
    Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 1992; 73:27372742.
  • 44
    Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:5968.
  • 45
    Xu X, Lindstrom SE, Shaw MW et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res 2004; 103:5560.
  • 46
    Higgins RR, Beniprashad M, Chong-King E et al. Recovery of influenza B Virus with the H273Y point mutation in the neuraminidase active site from a human patient. J Clin Microbiol 2012; 50:25002.
  • 47
    Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000; 10:4555.
  • 48
    Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010; 54:36713677.
  • 49
    Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002; 53:4761.